Hatim Sabaawy
Concepts (282)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Organoids | 3 | 2021 | 112 | 2.010 |
Why?
| | Neoplastic Stem Cells | 3 | 2016 | 400 | 1.030 |
Why?
| | Polycomb Repressive Complex 1 | 2 | 2017 | 50 | 1.030 |
Why?
| | Prostatic Neoplasms | 3 | 2021 | 1034 | 0.970 |
Why?
| | Antineoplastic Agents | 6 | 2021 | 2135 | 0.970 |
Why?
| | Glioblastoma | 2 | 2021 | 343 | 0.900 |
Why?
| | Bone Marrow Cells | 3 | 2014 | 316 | 0.870 |
Why?
| | Spinal Cord Injuries | 4 | 2014 | 212 | 0.800 |
Why?
| | Zebrafish | 9 | 2022 | 495 | 0.780 |
Why?
| | Bone Marrow Transplantation | 2 | 2014 | 287 | 0.770 |
Why?
| | Cell Culture Techniques | 2 | 2021 | 363 | 0.760 |
Why?
| | STAT Transcription Factors | 1 | 2021 | 17 | 0.750 |
Why?
| | Janus Kinases | 1 | 2021 | 15 | 0.750 |
Why?
| | Apoptosis Regulatory Proteins | 2 | 2012 | 188 | 0.730 |
Why?
| | Biological Assay | 1 | 2021 | 123 | 0.710 |
Why?
| | Xenograft Model Antitumor Assays | 4 | 2021 | 870 | 0.690 |
Why?
| | Hepatocytes | 1 | 2021 | 220 | 0.680 |
Why?
| | Hematopoietic Stem Cells | 3 | 2012 | 402 | 0.660 |
Why?
| | Precision Medicine | 2 | 2021 | 428 | 0.630 |
Why?
| | Cell Survival | 4 | 2016 | 1119 | 0.530 |
Why?
| | Small Molecule Libraries | 1 | 2017 | 95 | 0.520 |
Why?
| | Carcinoma, Hepatocellular | 2 | 2017 | 361 | 0.500 |
Why?
| | Cell Self Renewal | 1 | 2016 | 55 | 0.500 |
Why?
| | Erythroid Cells | 2 | 2012 | 10 | 0.500 |
Why?
| | Zebrafish Proteins | 4 | 2022 | 287 | 0.490 |
Why?
| | Cell Differentiation | 3 | 2012 | 1987 | 0.490 |
Why?
| | Radiation-Sensitizing Agents | 1 | 2015 | 43 | 0.460 |
Why?
| | Quinoxalines | 1 | 2015 | 66 | 0.450 |
Why?
| | Adenocarcinoma | 3 | 2013 | 939 | 0.440 |
Why?
| | Nanotechnology | 1 | 2015 | 126 | 0.440 |
Why?
| | Nerve Regeneration | 1 | 2014 | 59 | 0.440 |
Why?
| | Proto-Oncogene Proteins c-akt | 2 | 2022 | 436 | 0.430 |
Why?
| | Benzimidazoles | 1 | 2015 | 168 | 0.430 |
Why?
| | Brain Neoplasms | 2 | 2021 | 1242 | 0.420 |
Why?
| | Liver Neoplasms | 2 | 2017 | 785 | 0.410 |
Why?
| | Hematologic Neoplasms | 1 | 2015 | 155 | 0.410 |
Why?
| | Liver | 1 | 2021 | 1941 | 0.400 |
Why?
| | Megakaryocytes | 1 | 2012 | 34 | 0.390 |
Why?
| | Embryonic Development | 2 | 2013 | 118 | 0.390 |
Why?
| | Cell Adhesion | 1 | 2013 | 467 | 0.380 |
Why?
| | Cell Line, Tumor | 6 | 2022 | 3414 | 0.360 |
Why?
| | Core Binding Factor Alpha 2 Subunit | 2 | 2012 | 31 | 0.360 |
Why?
| | Inflammation | 1 | 2021 | 2836 | 0.340 |
Why?
| | Signal Transduction | 2 | 2021 | 5078 | 0.320 |
Why?
| | Hep G2 Cells | 2 | 2021 | 67 | 0.320 |
Why?
| | Immunohistochemistry | 3 | 2021 | 1734 | 0.320 |
Why?
| | Brain | 2 | 2021 | 2675 | 0.310 |
Why?
| | Animals | 20 | 2023 | 36862 | 0.300 |
Why?
| | Exercise Therapy | 1 | 2013 | 437 | 0.290 |
Why?
| | Fluorouracil | 2 | 1999 | 210 | 0.290 |
Why?
| | Interferon-alpha | 2 | 1999 | 198 | 0.280 |
Why?
| | Gene Knockdown Techniques | 3 | 2013 | 327 | 0.280 |
Why?
| | Receptors, Androgen | 2 | 2020 | 150 | 0.270 |
Why?
| | Lymphoma, AIDS-Related | 1 | 2007 | 14 | 0.270 |
Why?
| | Cell Transformation, Neoplastic | 2 | 2021 | 327 | 0.270 |
Why?
| | Mice, Inbred NOD | 2 | 2021 | 601 | 0.270 |
Why?
| | Lymphoproliferative Disorders | 1 | 2007 | 55 | 0.260 |
Why?
| | Neoplasms | 1 | 2021 | 2661 | 0.260 |
Why?
| | Colonic Neoplasms | 2 | 1999 | 256 | 0.260 |
Why?
| | Drug Resistance, Neoplasm | 2 | 2021 | 802 | 0.260 |
Why?
| | Cell Proliferation | 4 | 2021 | 2479 | 0.250 |
Why?
| | Lymphoma, Non-Hodgkin | 1 | 2007 | 87 | 0.250 |
Why?
| | Apoptosis | 6 | 2020 | 2554 | 0.240 |
Why?
| | Molecular Targeted Therapy | 2 | 2021 | 413 | 0.240 |
Why?
| | Disease Models, Animal | 4 | 2014 | 4284 | 0.240 |
Why?
| | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2006 | 80 | 0.240 |
Why?
| | F-Box Proteins | 2 | 2016 | 23 | 0.230 |
Why?
| | Heme Oxygenase (Decyclizing) | 2 | 2001 | 22 | 0.230 |
Why?
| | Humans | 27 | 2023 | 137294 | 0.230 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2006 | 215 | 0.220 |
Why?
| | Transplantation, Autologous | 3 | 2014 | 238 | 0.220 |
Why?
| | Mice | 8 | 2023 | 17774 | 0.200 |
Why?
| | Morpholinos | 2 | 2013 | 30 | 0.200 |
Why?
| | Ear, Inner | 1 | 2022 | 48 | 0.190 |
Why?
| | Genetic Therapy | 2 | 2001 | 296 | 0.190 |
Why?
| | Hepatocyte Nuclear Factor 4 | 1 | 2021 | 15 | 0.190 |
Why?
| | Phosphoenolpyruvate Carboxykinase (ATP) | 1 | 2021 | 15 | 0.190 |
Why?
| | Antimetabolites, Antineoplastic | 2 | 1999 | 94 | 0.190 |
Why?
| | Glucose-6-Phosphatase | 1 | 2021 | 33 | 0.190 |
Why?
| | Cell Shape | 1 | 2021 | 57 | 0.190 |
Why?
| | Freezing | 1 | 2021 | 91 | 0.180 |
Why?
| | SOX9 Transcription Factor | 2 | 2023 | 24 | 0.180 |
Why?
| | Combined Modality Therapy | 2 | 2021 | 1237 | 0.180 |
Why?
| | Genetic Heterogeneity | 1 | 2021 | 59 | 0.180 |
Why?
| | Culture Media | 1 | 2021 | 167 | 0.180 |
Why?
| | Albumins | 1 | 2021 | 113 | 0.180 |
Why?
| | Gene Transfer Techniques | 2 | 1999 | 169 | 0.180 |
Why?
| | Drug Screening Assays, Antitumor | 1 | 2021 | 195 | 0.180 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2021 | 184 | 0.170 |
Why?
| | Tumor Microenvironment | 2 | 2023 | 674 | 0.170 |
Why?
| | Fluorescent Antibody Technique | 1 | 2021 | 388 | 0.170 |
Why?
| | Carcinoma, Intraductal, Noninfiltrating | 1 | 2021 | 56 | 0.170 |
Why?
| | Prodrugs | 1 | 2021 | 52 | 0.170 |
Why?
| | Heterografts | 1 | 2021 | 138 | 0.170 |
Why?
| | Histological Techniques | 1 | 2020 | 40 | 0.170 |
Why?
| | Tumor Cells, Cultured | 3 | 2015 | 954 | 0.170 |
Why?
| | Biomarkers | 2 | 2021 | 4164 | 0.170 |
Why?
| | Androgen Antagonists | 1 | 2020 | 82 | 0.160 |
Why?
| | Gene Expression | 3 | 2012 | 1501 | 0.160 |
Why?
| | Disease Susceptibility | 1 | 2021 | 345 | 0.160 |
Why?
| | Printing, Three-Dimensional | 1 | 2020 | 94 | 0.160 |
Why?
| | Lung Neoplasms | 2 | 2023 | 2494 | 0.160 |
Why?
| | Protein Isoforms | 1 | 2020 | 403 | 0.150 |
Why?
| | Mitosis | 2 | 2012 | 193 | 0.150 |
Why?
| | Inflammation Mediators | 1 | 2021 | 514 | 0.150 |
Why?
| | Recovery of Function | 2 | 2014 | 657 | 0.150 |
Why?
| | Gene Expression Regulation | 2 | 2021 | 2608 | 0.140 |
Why?
| | Disease Management | 1 | 2021 | 627 | 0.140 |
Why?
| | Gene Expression Regulation, Developmental | 3 | 2013 | 858 | 0.130 |
Why?
| | Transduction, Genetic | 2 | 2012 | 126 | 0.130 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2022 | 684 | 0.130 |
Why?
| | Male | 10 | 2021 | 67560 | 0.130 |
Why?
| | Genetic Vectors | 2 | 2012 | 321 | 0.130 |
Why?
| | Biomarkers, Tumor | 2 | 2021 | 1274 | 0.130 |
Why?
| | Genomics | 1 | 2021 | 792 | 0.120 |
Why?
| | Disease Progression | 2 | 2021 | 2752 | 0.120 |
Why?
| | Retroviridae | 3 | 2001 | 99 | 0.120 |
Why?
| | Proteasome Endopeptidase Complex | 1 | 2016 | 155 | 0.120 |
Why?
| | Mice, SCID | 1 | 2016 | 367 | 0.120 |
Why?
| | Neurons | 3 | 2022 | 1588 | 0.120 |
Why?
| | Nanoparticles | 1 | 2021 | 484 | 0.120 |
Why?
| | Ubiquitin-Protein Ligases | 1 | 2016 | 176 | 0.120 |
Why?
| | HEK293 Cells | 1 | 2017 | 731 | 0.110 |
Why?
| | Contusions | 1 | 2014 | 20 | 0.110 |
Why?
| | Spinal Cord | 2 | 2014 | 370 | 0.110 |
Why?
| | Injections, Spinal | 1 | 2014 | 106 | 0.110 |
Why?
| | Blood Pressure | 1 | 2001 | 1776 | 0.110 |
Why?
| | Racemases and Epimerases | 1 | 2013 | 11 | 0.110 |
Why?
| | CHARGE Syndrome | 1 | 2013 | 1 | 0.110 |
Why?
| | Transcriptional Regulator ERG | 1 | 2013 | 18 | 0.110 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2022 | 1078 | 0.110 |
Why?
| | DNA Damage | 1 | 2016 | 422 | 0.110 |
Why?
| | Evoked Potentials, Somatosensory | 1 | 2013 | 33 | 0.100 |
Why?
| | Dogs | 1 | 2014 | 411 | 0.100 |
Why?
| | Jumonji Domain-Containing Histone Demethylases | 1 | 2013 | 62 | 0.100 |
Why?
| | Collagen Type I | 1 | 2013 | 133 | 0.100 |
Why?
| | Prostate-Specific Antigen | 1 | 2013 | 161 | 0.100 |
Why?
| | Microscopy, Fluorescence | 1 | 2014 | 397 | 0.100 |
Why?
| | Lentivirus | 1 | 2012 | 56 | 0.100 |
Why?
| | K562 Cells | 1 | 2012 | 89 | 0.100 |
Why?
| | Antigens, CD34 | 1 | 2012 | 88 | 0.100 |
Why?
| | Cytarabine | 1 | 2012 | 61 | 0.100 |
Why?
| | Cell Cycle Proteins | 1 | 2016 | 613 | 0.100 |
Why?
| | Erythropoiesis | 1 | 2012 | 55 | 0.100 |
Why?
| | Gene Expression Regulation, Leukemic | 1 | 2012 | 54 | 0.100 |
Why?
| | Cell- and Tissue-Based Therapy | 1 | 2013 | 82 | 0.100 |
Why?
| | Single-Blind Method | 1 | 2013 | 286 | 0.100 |
Why?
| | HIV Infections | 1 | 2007 | 2820 | 0.100 |
Why?
| | Hypertension | 1 | 2001 | 1285 | 0.090 |
Why?
| | Adult | 4 | 2021 | 37724 | 0.090 |
Why?
| | DNA Helicases | 1 | 2013 | 145 | 0.090 |
Why?
| | Embryo, Nonmammalian | 1 | 2012 | 167 | 0.090 |
Why?
| | Motor Activity | 2 | 2014 | 719 | 0.090 |
Why?
| | Mice, Nude | 1 | 2013 | 696 | 0.090 |
Why?
| | Organ Specificity | 1 | 2012 | 304 | 0.090 |
Why?
| | Tachykinins | 1 | 2011 | 6 | 0.090 |
Why?
| | Spinal Cord Regeneration | 1 | 2011 | 2 | 0.090 |
Why?
| | Antigens, CD | 1 | 2014 | 522 | 0.090 |
Why?
| | Hematopoiesis | 1 | 2012 | 190 | 0.090 |
Why?
| | Neovascularization, Physiologic | 1 | 2012 | 178 | 0.090 |
Why?
| | Trans-Activators | 1 | 2013 | 398 | 0.090 |
Why?
| | Cancer Vaccines | 1 | 2012 | 173 | 0.090 |
Why?
| | RNA Interference | 1 | 2012 | 467 | 0.090 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2015 | 2052 | 0.080 |
Why?
| | Leukemia | 1 | 2012 | 238 | 0.080 |
Why?
| | Transcription Factors | 2 | 2022 | 1720 | 0.080 |
Why?
| | Molecular Sequence Data | 3 | 2013 | 2904 | 0.080 |
Why?
| | Animals, Genetically Modified | 2 | 2007 | 240 | 0.080 |
Why?
| | Dendritic Cells | 1 | 2012 | 484 | 0.080 |
Why?
| | Transfection | 2 | 2020 | 947 | 0.070 |
Why?
| | Breast Neoplasms | 1 | 2021 | 2243 | 0.070 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2012 | 530 | 0.070 |
Why?
| | Base Sequence | 2 | 2013 | 2182 | 0.070 |
Why?
| | Repressor Proteins | 1 | 2011 | 427 | 0.070 |
Why?
| | RNA-Binding Protein EWS | 1 | 2007 | 26 | 0.070 |
Why?
| | Immunotherapy | 1 | 2012 | 641 | 0.070 |
Why?
| | Nerve Tissue Proteins | 1 | 2011 | 596 | 0.070 |
Why?
| | Middle Aged | 4 | 2015 | 33310 | 0.070 |
Why?
| | Sequence Homology, Nucleic Acid | 1 | 2007 | 154 | 0.070 |
Why?
| | Chronic Disease | 1 | 2013 | 1788 | 0.070 |
Why?
| | bcl-2-Associated X Protein | 1 | 2006 | 56 | 0.070 |
Why?
| | RNA, Messenger | 3 | 2013 | 2839 | 0.060 |
Why?
| | DNA-Binding Proteins | 1 | 2013 | 1501 | 0.060 |
Why?
| | Gene Silencing | 1 | 2006 | 195 | 0.060 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2006 | 234 | 0.060 |
Why?
| | Gene Expression Profiling | 1 | 2012 | 1774 | 0.060 |
Why?
| | Heme Oxygenase-1 | 2 | 2001 | 64 | 0.060 |
Why?
| | DNA, Neoplasm | 1 | 2005 | 164 | 0.060 |
Why?
| | MicroRNAs | 1 | 2011 | 699 | 0.050 |
Why?
| | Rats | 3 | 2021 | 5639 | 0.050 |
Why?
| | Female | 6 | 2021 | 73052 | 0.050 |
Why?
| | RNA-Binding Proteins | 1 | 2007 | 424 | 0.050 |
Why?
| | Up-Regulation | 1 | 2006 | 844 | 0.050 |
Why?
| | Biopsy | 1 | 2007 | 1127 | 0.050 |
Why?
| | Genes, ras | 1 | 2023 | 97 | 0.050 |
Why?
| | Central Nervous System Neoplasms | 1 | 2005 | 158 | 0.050 |
Why?
| | Carboplatin | 1 | 2022 | 143 | 0.050 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2022 | 95 | 0.050 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2023 | 267 | 0.050 |
Why?
| | Mechanistic Target of Rapamycin Complex 1 | 1 | 2022 | 125 | 0.050 |
Why?
| | Polymerase Chain Reaction | 1 | 2005 | 1061 | 0.050 |
Why?
| | Protein Binding | 3 | 2016 | 2225 | 0.050 |
Why?
| | Culture Techniques | 1 | 2001 | 81 | 0.050 |
Why?
| | Rats, Inbred SHR | 1 | 2001 | 45 | 0.050 |
Why?
| | Pyrazines | 1 | 2022 | 91 | 0.050 |
Why?
| | Chimera | 1 | 2001 | 59 | 0.050 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2005 | 288 | 0.050 |
Why?
| | Paclitaxel | 1 | 2022 | 227 | 0.040 |
Why?
| | Arterioles | 1 | 2001 | 52 | 0.040 |
Why?
| | Treatment Outcome | 2 | 2013 | 10800 | 0.040 |
Why?
| | Triazoles | 1 | 2022 | 147 | 0.040 |
Why?
| | Neurogenesis | 1 | 2022 | 147 | 0.040 |
Why?
| | Magnetic Resonance Imaging | 1 | 2013 | 3568 | 0.040 |
Why?
| | Models, Biological | 3 | 2016 | 1773 | 0.040 |
Why?
| | Pressure | 1 | 2001 | 222 | 0.040 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2022 | 365 | 0.040 |
Why?
| | Vasoconstriction | 1 | 2001 | 202 | 0.040 |
Why?
| | Spheroids, Cellular | 1 | 2020 | 76 | 0.040 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2022 | 412 | 0.040 |
Why?
| | Blotting, Northern | 1 | 1999 | 200 | 0.040 |
Why?
| | 3T3 Cells | 1 | 1999 | 163 | 0.040 |
Why?
| | Neural Stem Cells | 1 | 2020 | 155 | 0.040 |
Why?
| | DNA, Complementary | 1 | 1999 | 271 | 0.040 |
Why?
| | Drug Synergism | 1 | 1999 | 383 | 0.040 |
Why?
| | Aged | 2 | 2015 | 23851 | 0.040 |
Why?
| | Weight Gain | 1 | 2001 | 519 | 0.030 |
Why?
| | Cell Division | 1 | 1999 | 796 | 0.030 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 1999 | 976 | 0.030 |
Why?
| | F-Box-WD Repeat-Containing Protein 7 | 1 | 2016 | 6 | 0.030 |
Why?
| | Oligonucleotides, Antisense | 2 | 2011 | 111 | 0.030 |
Why?
| | Glycogen Synthase Kinase 3 beta | 1 | 2016 | 72 | 0.030 |
Why?
| | Ubiquitination | 1 | 2016 | 102 | 0.030 |
Why?
| | Young Adult | 1 | 2013 | 13163 | 0.030 |
Why?
| | Proteolysis | 1 | 2016 | 178 | 0.030 |
Why?
| | Protein Interaction Domains and Motifs | 1 | 2016 | 151 | 0.030 |
Why?
| | DNA | 1 | 2022 | 1459 | 0.030 |
Why?
| | Membrane Proteins | 1 | 2001 | 1163 | 0.030 |
Why?
| | Cell Death | 1 | 2016 | 372 | 0.030 |
Why?
| | Ultraviolet Rays | 1 | 2016 | 390 | 0.030 |
Why?
| | Adolescent | 1 | 2013 | 21499 | 0.030 |
Why?
| | Gene Targeting | 1 | 2013 | 81 | 0.030 |
Why?
| | Kidney | 1 | 2001 | 1467 | 0.030 |
Why?
| | RNA, Ribosomal | 1 | 2013 | 168 | 0.020 |
Why?
| | Hepatic Encephalopathy | 1 | 2012 | 21 | 0.020 |
Why?
| | Neural Crest | 1 | 2013 | 116 | 0.020 |
Why?
| | Lymphocyte Count | 1 | 2012 | 150 | 0.020 |
Why?
| | Liver Function Tests | 1 | 2012 | 114 | 0.020 |
Why?
| | Cartilage | 1 | 2013 | 188 | 0.020 |
Why?
| | Phosphorylation | 1 | 2016 | 1759 | 0.020 |
Why?
| | Activating Transcription Factors | 1 | 2011 | 2 | 0.020 |
Why?
| | Co-Repressor Proteins | 1 | 2011 | 18 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-jun | 1 | 2011 | 55 | 0.020 |
Why?
| | Fibroblast Growth Factor 2 | 1 | 2011 | 87 | 0.020 |
Why?
| | Transcription Factor AP-1 | 1 | 2011 | 92 | 0.020 |
Why?
| | Response Elements | 1 | 2011 | 91 | 0.020 |
Why?
| | Transplantation, Heterologous | 1 | 2011 | 195 | 0.020 |
Why?
| | rhoA GTP-Binding Protein | 1 | 2011 | 86 | 0.020 |
Why?
| | Genes, Reporter | 1 | 2011 | 269 | 0.020 |
Why?
| | Cyclic AMP Response Element-Binding Protein | 1 | 2011 | 145 | 0.020 |
Why?
| | Tretinoin | 1 | 2011 | 123 | 0.020 |
Why?
| | Cell Cycle | 1 | 2013 | 601 | 0.020 |
Why?
| | Child | 2 | 2006 | 21999 | 0.020 |
Why?
| | Lung | 1 | 2022 | 4067 | 0.020 |
Why?
| | Interferon-gamma | 1 | 2012 | 790 | 0.020 |
Why?
| | Flow Cytometry | 1 | 2012 | 1184 | 0.020 |
Why?
| | Binding Sites | 1 | 2011 | 1309 | 0.020 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2007 | 387 | 0.020 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2012 | 916 | 0.020 |
Why?
| | Palliative Care | 1 | 2012 | 747 | 0.020 |
Why?
| | Preservation, Biological | 1 | 2005 | 8 | 0.010 |
Why?
| | Phenotype | 1 | 2013 | 3202 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2011 | 4197 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 2007 | 2147 | 0.010 |
Why?
| | Follow-Up Studies | 1 | 2012 | 5125 | 0.010 |
Why?
| | Tomography, X-Ray Computed | 1 | 2012 | 2679 | 0.010 |
Why?
| | Time Factors | 1 | 2012 | 6818 | 0.010 |
Why?
| | Tin Compounds | 1 | 2001 | 17 | 0.010 |
Why?
| | Heme | 1 | 2001 | 78 | 0.010 |
Why?
| | Tissue Distribution | 1 | 2001 | 330 | 0.010 |
Why?
| | In Vitro Techniques | 1 | 2001 | 1089 | 0.010 |
Why?
| | Prognosis | 1 | 2005 | 4026 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 2001 | 2486 | 0.010 |
Why?
|
|
Sabaawy's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|